A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients

Table 2 Treatment characteristics

Patient	CKD	Fondaparinux dose	Duration of fondaparinux (days)	Transitioned and discharged on warfarin (Y/N)	Concurrent aspirin dosage	New thrombosis after fondaparinux*	Major bleeding after fondaparinux
1	Y	2.5 mg	5	Y	81 mg	No	No
2	N	2.5 mg	22	N	81 mg	LVAD thrombosis	No
3	N	5 mg	14	Y	325 mg	No	No
4	N	5 mg	4	Y	325 mg	No	No
5	N	5 mg	3	Y	81 mg	PE	No
6	N	7.5 mg	10	Y	81 mg	DVT	Overt bleed**
7	N	7.5 mg	3	N	81 mg	No	Blood transfusion***
8	Y	10 mg	2	Y	81 mg	No	Blood transfusion***

*All thrombotic events occurred prior to discharge on the admission in which HIT was diagnosed.
**Overt bleeding = ≥ 2 gram g/dL decrease in any 24 hr period.
***Believed to be related to clinical course and unrelated to anticoagulation therapy.
CKD = chronic kidney disease; defined as estimated glomerular filtration rate (GFR) < 60 mL/min/1.73 m2 for > 3 months.
DVT = deep vein thrombosis.
PE = pulmonary embolism.

ISSN: 1749-8090